PRaG 3.0 therapy for human epidermal growth factor receptor 2-positive metastatic pancreatic ductal adenocarcinoma: A case report.
Yue-Hong KongMei-Ling XuJun-Jun ZhangGuang-Qiang ChenZhi-Hui HongHong ZhangXiao-Xiao DaiYi-Fu MaXiang-Rong ZhaoChen-Yang ZhangRong-Zheng ChenPeng-Fei XingLi-Yuan ZhangPublished in: World journal of gastroenterology (2024)
PRaG 3.0 might be a novel strategy for HER2-positive metastatic PDAC patients who failed from previous first-line approach and even PD-1 immunotherapy but needs more data in prospective trials.